文献速递乳腺癌

内分泌治疗在雌激素受体阳性pT1a-b乳腺癌中的作用:一项回顾性研究结果

Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study.
PubMed 文献 · Eur J Cancer · 2022-10-01

本研究纳入15个法国中心5545例pT1a-b期雌激素受体阳性乳腺癌患者,回顾性分析内分泌治疗与生存的关系。80.3%(4453例)接受内分泌治疗;未接受内分泌治疗与无病生存期(DFS)下降显著相关(HR=1.275,p=0.047,95%CI[1.003-1.620]),但总生存期(OS)与无复发生存期(RFS)无显著关联;在组织学分级2-3级患者中未接受内分泌治疗与DFS下降显著相关(HR=1.502,p=0.049,95%CI[1.001-2.252]),分级1级患者中未观察到显著生存获益。

要点

  • 5545例pT1a-b期ER阳性乳腺癌中80.3%接受内分泌治疗。
  • 全体患者中未接受内分泌治疗与DFS下降显著相关,HR=1.275,p=0.047。
  • 分级2-3级患者中未接受内分泌治疗与DFS下降显著相关,HR=1.502,p=0.049;分级1级患者未见显著关联。

核心结论

  • 研究结果提示内分泌治疗对pT1a-bN0期ER阳性乳腺癌患者生存有益,尤其在组织学分级2-3级肿瘤中;分级1级肿瘤中未观察到该作用。
  • 作者认为应与这类患者讨论内分泌治疗,尤其是pT1a分级1级肿瘤患者。

研究设计与样本

  • 回顾性观察性研究,纳入15个法国中心5545例接受治疗的pT1a-b期ER阳性乳腺癌患者。
  • 排除HER2阳性、接受新辅助化疗、ER阴性、pN状态未知或原位癌的患者。
  • 采用单因素分析和多因素Cox回归估计无病生存期(DFS)、无复发生存期(RFS)和总生存期(OS)。

主要发现

  • 80.3%(4453例)患者接受内分泌治疗。
  • 与未接受内分泌治疗者相比,接受内分泌治疗者在随访5年和7年时DFS分别提高2.5%和3.3%,RFS分别提高1.9%和4.3%,OS差异很小。
  • Cox回归分析中,全体患者未接受内分泌治疗与DFS下降显著相关(HR=1.275,p=0.047,95%CI[1.003-1.620]),与OS、RFS无显著关联。
  • 2363例pT1a-b期ER阳性分级2-3级患者中,未接受内分泌治疗与DFS下降显著相关(HR=1.502,p=0.049,95%CI[1.001-2.252]),与OS无显著关联(HR=1.361,p=0.272)。
  • 3047例pT1a-b期ER阳性分级1级患者中,省略内分泌治疗与生存下降无显著关联。

临床怎么用

  • 作者认为应与pT1a-bN0期ER阳性乳腺癌患者讨论内分泌治疗,尤其是pT1a分级1级肿瘤患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Few data have been reported regarding endocrine therapy (ET) in patients with small pT1a-b ER-postive breast cancer (BC). Thus, we conducted a study to detect possible survival improvements due to ET in such patients. METHODS: Our retrospective observational study included 5545 patients with pT1a-b ER-positive BC treated in 15 French centres, excluding patients with HER2-positive status, neoadjuvant chemotherapy, ER-negative status, unknown pN status or in situ BC. We estimated disease-free survival (DFS), recurrence-free survival (RFS) and overall survival (OS) via univariate analysis and multivariate Cox regression. RESULTS: Most patients (80.3%: 4453) received ET and-when compared to those without ET-experienced increases of 2.5% and 3.3% in DFS and 1.9% and 4.3% in RFS after 5 and 7 years of follow-up, respectively, with little difference in OS. In Cox regression analysis, no ET was significantly associated with decreased DFS (hazard ratio, HR = 1.275, p = 0.047, 95% CI[1.003-1.620]) but not OS or RFS in all patients, while in 2363 patients with pT1a-b ER-positive grade 2-3 BC, no ET was significantly associated with decreased DFS (HR = 1.502, p = 0.049, 95% CI[1.001-2.252]), but not OS (HR = 1.361, p = 0.272). ET omission was not significantly associated with decreased survival in 3047 patients with pT1a-b ER-positive grade 1 BC. CONCLUSION: Our results indicate that while ET provided a beneficial impact on survival to patients with pT1a-bN0 ER-positive BC-and especially in those with grade 2-3 tumours-no such impact was observed in grade 1 tumours. Consequently, ET should be discussed with these patients, particularly in those with pT1a grade 1 tumours.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Houvenaeghel G, de Nonneville A, Cohen M, et al. Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study. Eur J Cancer. 2022. PMID: 36194904. doi:10.1016/j.ejca.2022.08.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。